Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01445080 · OUTCOME

Leukemia Mutations

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia · Source last updated 2021-02-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
1 week prior to enrollment

What was measured

Analyze tumor samples and leukemic blasts from patients entered on this study for the presence of ras, raf, or FLT3 (leukemia) mutations.

Analysis population: This data were not and will never be collected

Groups in this outcome

Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^2

Patients receive oral sorafenib 150 mg/m\^2 every 12 hours.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^20

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Analyze tumor samples and leukemic blasts from patients entered on this study for the presence of ras, raf, or FLT3 (leukemia) mutations.
groups
  1. description
    Patients receive oral sorafenib 150 mg/m\^2 every 12 hours.
    id
    OG000
    title
    Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^2
population Description
This data were not and will never be collected
reporting Status
POSTED
time Frame
1 week prior to enrollment
title
Leukemia Mutations
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice